KR100293867B1 - 아미노스틸바졸유도체및의약 - Google Patents

아미노스틸바졸유도체및의약 Download PDF

Info

Publication number
KR100293867B1
KR100293867B1 KR1019960705560A KR19960705560A KR100293867B1 KR 100293867 B1 KR100293867 B1 KR 100293867B1 KR 1019960705560 A KR1019960705560 A KR 1019960705560A KR 19960705560 A KR19960705560 A KR 19960705560A KR 100293867 B1 KR100293867 B1 KR 100293867B1
Authority
KR
South Korea
Prior art keywords
carbon atoms
amino
phenyl
ethenyl
sulfonyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
KR1019960705560A
Other languages
English (en)
Korean (ko)
Other versions
KR970702253A (ko
Inventor
히로요시 히다카
아키라 마츠우라
마사토 마츠다
Original Assignee
니뽄 신야쿠 가부시키가이샤
히로요시 히다카
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 니뽄 신야쿠 가부시키가이샤, 히로요시 히다카 filed Critical 니뽄 신야쿠 가부시키가이샤
Publication of KR970702253A publication Critical patent/KR970702253A/ko
Assigned to 유겐가이샤 디. 웨스턴 세라퓨틱스 겐큐죠 reassignment 유겐가이샤 디. 웨스턴 세라퓨틱스 겐큐죠 권리지분의 전부이전등록 Assignors: 히다카 히로요시
Application granted granted Critical
Publication of KR100293867B1 publication Critical patent/KR100293867B1/ko
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/42—Radicals substituted by singly-bound nitrogen atoms having hetero atoms attached to the substituent nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/76—Nitrogen atoms to which a second hetero atom is attached
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/12—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Cephalosporin Compounds (AREA)
KR1019960705560A 1994-04-06 1995-04-05 아미노스틸바졸유도체및의약 Expired - Lifetime KR100293867B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP6825294 1994-04-06
JP94-068252 1994-04-06
PCT/JP1995/000658 WO1995027699A1 (en) 1994-04-06 1995-04-05 Aminostilbazole derivative and medicine

Publications (2)

Publication Number Publication Date
KR970702253A KR970702253A (ko) 1997-05-13
KR100293867B1 true KR100293867B1 (ko) 2001-09-17

Family

ID=13368389

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019960705560A Expired - Lifetime KR100293867B1 (ko) 1994-04-06 1995-04-05 아미노스틸바졸유도체및의약

Country Status (14)

Country Link
US (1) US5972976A (cg-RX-API-DMAC7.html)
EP (1) EP0754682B9 (cg-RX-API-DMAC7.html)
JP (1) JP3080405B2 (cg-RX-API-DMAC7.html)
KR (1) KR100293867B1 (cg-RX-API-DMAC7.html)
CN (1) CN1053658C (cg-RX-API-DMAC7.html)
AT (1) ATE207057T1 (cg-RX-API-DMAC7.html)
CA (1) CA2187214C (cg-RX-API-DMAC7.html)
DE (1) DE69523298T2 (cg-RX-API-DMAC7.html)
DK (1) DK0754682T3 (cg-RX-API-DMAC7.html)
ES (1) ES2165911T3 (cg-RX-API-DMAC7.html)
PT (1) PT754682E (cg-RX-API-DMAC7.html)
RU (1) RU2138482C1 (cg-RX-API-DMAC7.html)
TW (1) TW308586B (cg-RX-API-DMAC7.html)
WO (1) WO1995027699A1 (cg-RX-API-DMAC7.html)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1072688B1 (en) * 1998-04-15 2004-06-30 Hiroyoshi Hidaka Method for in vivo detecting a target protein gene by a drug
AU3895299A (en) * 1998-05-12 1999-11-29 Wen Y Chen Use of anti-prolactin agents to treat proliferative conditions
JP3849428B2 (ja) * 1999-04-23 2006-11-22 日本新薬株式会社 微粉化法
US6521658B1 (en) 1999-05-28 2003-02-18 Abbott Laboratories Cell proliferation inhibitors
DE60034963D1 (de) * 1999-12-14 2007-07-05 Nippon Shinyaku Co Ltd Heterocyclische derivate und arzneistoffe
JP2004359545A (ja) * 2001-03-08 2004-12-24 D Western Therapeutics Institute 抗癌剤耐性克服剤
US6967211B2 (en) * 2001-04-10 2005-11-22 Nippon Shinyaku Co. Ltd. Remedial agent for chronic articular rheumatism
US7148244B2 (en) 2001-04-26 2006-12-12 Nippon Shinyaku Co. Ltd. Medicines in controlling Vpr function
US6951875B2 (en) * 2001-10-29 2005-10-04 Hoffmann-La Roche Inc. Conjugated aromatic compounds with a pyridine substituent
FR2838437B1 (fr) * 2002-04-11 2004-06-04 Aventis Pharma Sa Procedes de preparation de combretastatines
AU2003261951A1 (en) * 2002-09-06 2004-03-29 D. Western Therapeutics Institute Medicinal composition and method for treating malignant tumor and utilization thereof
WO2006078941A2 (en) * 2005-01-20 2006-07-27 Sirtris Pharmaceuticals, Inc. Novel sirtuin activating compounds and methods of use thereof
WO2007137196A2 (en) * 2006-05-19 2007-11-29 Threshold Pharmaceuticals, Inc. Tubulin binding anti cancer compounds and prodrugs thereof
US20100198262A1 (en) * 2009-01-30 2010-08-05 Mckinley Laurence M Axial offset bone fastener system
MX2015014470A (es) * 2013-04-19 2016-02-22 Univ Arkansas Analogos de combretastatina.
EP3080057B1 (de) 2013-12-13 2019-03-20 EuroChem Agro GmbH Nitrifikationsinhibitor enthaltende düngemittelmischung
AU2015240880A1 (en) 2014-03-31 2016-09-15 Bioventures, Llc Disubstituted triazole analogs
DE102017201608A1 (de) 2017-02-01 2018-08-02 Eurochem Agro Gmbh 3,4-Dimethylpyrazol enthaltende Mischung und ihre Verwendung
WO2018144910A1 (en) 2017-02-02 2018-08-09 Bioventures, Llc Methods of protecting against neurodegeneration
CN112110829B (zh) * 2019-06-19 2023-08-01 复旦大学 一种能结合α-突触核蛋白聚集体的小分子化合物、其制备方法及其用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE167473T1 (de) * 1990-08-20 1998-07-15 Eisai Co Ltd Sulfonamid-derivate
JP2790926B2 (ja) * 1990-08-20 1998-08-27 エーザイ株式会社 スルホンアミド誘導体
JP2692467B2 (ja) * 1991-12-09 1997-12-17 ダイキン工業株式会社 空調制御装置の電力供給装置
DE69221290T2 (de) * 1991-12-10 1998-01-15 Shionogi & Co Auf aromatischen sulfonamiden basierende hydroxamsäurederivate

Also Published As

Publication number Publication date
EP0754682A4 (en) 1998-03-04
RU2138482C1 (ru) 1999-09-27
EP0754682B9 (en) 2003-09-17
WO1995027699A1 (en) 1995-10-19
KR970702253A (ko) 1997-05-13
ATE207057T1 (de) 2001-11-15
EP0754682A1 (en) 1997-01-22
JP3080405B2 (ja) 2000-08-28
PT754682E (pt) 2002-03-28
CA2187214A1 (en) 1995-10-19
CN1145066A (zh) 1997-03-12
TW308586B (cg-RX-API-DMAC7.html) 1997-06-21
MX9604540A (es) 1997-09-30
EP0754682B1 (en) 2001-10-17
DE69523298T2 (de) 2002-06-27
DK0754682T3 (da) 2002-02-04
CN1053658C (zh) 2000-06-21
US5972976A (en) 1999-10-26
ES2165911T3 (es) 2002-04-01
DE69523298D1 (de) 2001-11-22
CA2187214C (en) 2002-03-12

Similar Documents

Publication Publication Date Title
JP3080405B2 (ja) アミノスチルバゾール誘導体及び医薬
EP0540099B1 (en) Water soluble camptothecin derivatives
RU2241000C2 (ru) Гетероциклические соединения с замещенной фенильной группировкой, способ их получения (варианты), фармацевтические препараты на их основе и способ ингибирования секреции желудочной кислоты
EP3964504A1 (en) Benzothiophene compound, preparation method therefor and use thereof
WO1999024432A1 (fr) Derives de purine et medicament les renfermant en tant qu'ingredient actif
US9273005B2 (en) Hydroxypyridone derivatives, pharmaceutical compositions thereof, and their therapeutic use for treating proliferative diseases
WO1997037989A1 (en) Indole derivatives as 5-ht receptor antagonist
JPWO1995027699A1 (ja) アミノスチルバゾール誘導体及び医薬
JP2572115B2 (ja) 抗増殖剤として有用な５−アミノ又は置換アミノ−１，２，３− トリアゾール類
EP0228959B1 (en) Aminostyryl compound, leukotriene antagonistic composition containing the same as effective ingredients and method of antagonizing srs by employing the same
EP3615027B1 (en) Methods of use for trisubstituted benzotriazole derivatives as dihydroorotate oxygenase inhibitors
JPS6344572A (ja) 抗不整脈剤
US11267810B2 (en) Aminopyrimidine compound and composition comprising same and use thereof
EP1560818A1 (en) Non-peptide gnrh agents, pharmaceutical compositions and methods for their use
CN111606890A (zh) 含丙烯酰基的核转运调节剂及其用途
US5250545A (en) Cancer cell metastasis inhibitor methods
JPH0372061B2 (cg-RX-API-DMAC7.html)
WO2019001307A1 (zh) 一种酰胺类化合物及包含该化合物的组合物及其用途
CN108368117A (zh) 一种取代的咪唑并喹唑啉化合物及其药物组合物
EP4006027A1 (en) Pyridine derivative as fgfr and vegfr dual inhibitors
JPS61158980A (ja) ８α‐アシルアミノエルゴリン類、その製法および医薬組成物
US6919455B2 (en) Purine derivative dihydrate, drugs containing the same as the active ingredient and intermediate in the production thereof
EP0335408A2 (en) Substituted benzene derivatives, processes for their production and antitumour compositions containing them
CN117050055A (zh) 含有酰胺吡啶环的化合物
JPH0665668B2 (ja) フエニルピラジン誘導体および抗血栓剤

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 19961005

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 19981211

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20000830

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20010402

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20010409

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20010410

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
G170 Re-publication after modification of scope of protection [patent]
PR1001 Payment of annual fee

Payment date: 20040206

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20050322

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee

Payment date: 20060327

Start annual number: 6

End annual number: 6

PR1001 Payment of annual fee

Payment date: 20070404

Start annual number: 7

End annual number: 7

PR1001 Payment of annual fee

Payment date: 20080331

Start annual number: 8

End annual number: 8

PR1001 Payment of annual fee

Payment date: 20090326

Start annual number: 9

End annual number: 9

PR1001 Payment of annual fee

Payment date: 20100323

Start annual number: 10

End annual number: 10

PR1001 Payment of annual fee

Payment date: 20110318

Start annual number: 11

End annual number: 11

PR1001 Payment of annual fee

Payment date: 20120322

Start annual number: 12

End annual number: 12

FPAY Annual fee payment

Payment date: 20130321

Year of fee payment: 13

PR1001 Payment of annual fee

Payment date: 20130321

Start annual number: 13

End annual number: 13

FPAY Annual fee payment

Payment date: 20140319

Year of fee payment: 14

PR1001 Payment of annual fee

Payment date: 20140319

Start annual number: 14

End annual number: 14

EXPY Expiration of term
PC1801 Expiration of term

Termination date: 20151005

Termination category: Expiration of duration